We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Boehringer Ingelheim Threatened With Fines for Noncompliance With 340B Drug Discount Program
Boehringer Ingelheim Threatened With Fines for Noncompliance With 340B Drug Discount Program
German drugmaker Boehringer Ingelheim (BI) is the latest biopharmaceutical company to get a letter from HHS saying the company’s unwillingness to participate in the controversial 340B drug discount program has been referred to the HHS Office of Inspector General.